Sign in
4

Changes in Ownership

AGIOS PHARMACEUTICALS, INC. Filed Acc 0001439222-26-000044

Chief Executive Officer sold 18,055 shares at $28.96 ($522,873)

  • Chief Executive Officer acquired 39,500 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Goff Brian · Chief Executive Officer

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2026-03-02 Exercise or conversion : show line 1 in the form 10b5-1 +8,500 151,603 D
2026-03-02 Sale : show line 2 in the form 10b5-1 −3,870 $28.96 $112,075 147,733 D
2026-03-02 Exercise or conversion : show line 3 in the form 10b5-1 +18,000 165,733 D
2026-03-02 Sale : show line 4 in the form 10b5-1 −8,267 $28.96 $239,412 157,466 D
2026-03-02 Exercise or conversion : show line 5 in the form 10b5-1 +13,000 170,466 D
2026-03-02 Sale : show line 6 in the form 10b5-1 −5,918 $28.96 $171,385 164,548 D
Open-market sales · 18,055 sh · avg $28.96 · $522,873

Table II: Derivative

5 lines
Date Transaction Shares Owned after D/I
2026-03-01 Grant or award : show line 7 in the form 10b5-1 Restricted stock units +48,000 48,000 D
2026-03-01 Grant or award : show line 8 in the form 10b5-1 Stock options (right to buy) +174,000 174,000 D
2026-03-02 Exercise or conversion : show line 9 in the form 10b5-1 Restricted stock units −8,500 0 D
2026-03-02 Exercise or conversion : show line 10 in the form 10b5-1 Restricted stock units −18,000 18,000 D
2026-03-02 Exercise or conversion : show line 11 in the form 10b5-1 Restricted stock units −13,000 26,000 D
Loading xslF345X05/wk-form4_1772572669.xml…